A Study of TG103 Injection in Type 2 Diabetes Subjects

NCT05348122 on ClinicalTrials.gov · last registry update 2022-06-13

An unusually large phase 2: 240 participants, more than double the 110 typical for the stage. Its estimated completion date, 1 November 2023, has passed with no update to the record. Primary outcome, as filed: Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Sponsor type: Industry
Enrollment: 240
Started: 2022-06-15
Primary completion: 2023-11-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.